Search

There is a close relationship between the gut microbiome and health in humans including regulation of immunity and energy metabolism. This study investigated differences in the gut microbiome of herdsmen from two regions: Hongyuan pasture in Sichuan and Xilingol pasture in Inner Mongolia. We found significant differences in the gut microbiome between the two groups. The main discriminatory species between the two groups were Bifidobacterium longum, Bifidobacterium breve, Phascolarctobacterium succinatutens, Prevotella stercorea, Prevotella copri, Eubacterium biforme, and Fusobacterium prausnitzii. The abundances of Bifidobacterium longum and Bifidobacterium breve were significantly lower in the gut microbiomes of Hongyuan herdsmen than in the gut microbiomes of Xilingol herdsmen. Functional metagenomic analysis showed that more genes were enriched in glycoside hydrolase and transposase in the gut microbiome of Hongyuan herdsmen compared with Xilingol herdsmen, suggesting a higher energy demand in the gut microbiome of Hongyuan herdsmen. Significantly more genes associated with glycolysis, starch degradation, and sucrose degradation were also found in the gut microbiome of Hong yuan herdsmen compared with Xilingol herdsmen. These results indicate that herdsmen from different pastoral regions had distinct gut microbiome composition and functions. [ABSTRACT FROM AUTHOR]

Summary: This was a pilot study aiming to evaluate the effects of probiotics as adjunctive treatment for ulcerative colitis (UC). Twenty‐five active patients with UC were assigned to the probiotic (n = 12) and placebo (n = 13) groups. The probiotic group received mesalazine (60 mg kg−1 day−1) and oral probiotics (containing Lactobacillus casei Zhang, Lactobacillus plantarum P‐8 and Bifidobacterium animalis subsp. lactis V9) twice daily for 12 weeks, while the placebo group received the same amounts of mesalazine and placebo. The clinical outcomes were assessed. The gut mucosal microbiota was profiled by PacBio single‐molecule, real‐time (SMRT) sequencing of the full‐length 16S rRNA of biopsy samples obtained by colonoscopy. A significantly greater magnitude of reduction was observed in the UC disease activity index (UCDAI) in the probiotic group compared with the placebo group (P = 0.043), accompanying by a higher remission rate (91.67% for probiotic‐receivers versus 69.23% for placebo‐receivers, P = 0.034). The probiotics could protect from diminishing of the microbiota diversity and richness. Moreover, the gut mucosal microbiota of the probiotic‐receivers had significantly more beneficial bacteria like Eubacterium ramulus (P < 0.05), Pediococcus pentosaceus (P < 0.05), Bacteroides fragilis (P = 0.02) and Weissella cibaria (P = 0.04). Additionally, the relative abundances of the beneficial bacteria correlated significantly but negatively with the UCDAI score, suggesting that the probiotics might alleviate UC symptoms by modulating the gut mucosal microbiota. Our research has provided new insights into the mechanism of symptom alleviation in UC by applying probiotic‐based adjunctive treatment. [ABSTRACT FROM AUTHOR]